Forbion European Acquisition Corp. (FRBN) to Combine with enGene
Forbion European Acquisition Corp. (NASDAQ:FRBN) has entered into a definitive agreement to combine with biotech firm enGene. Montreal-based company enGene is developing non-viral gene therapies to treat cancers and other conditions. The combined company is expected to trade on the Nasdaq once the deal is completed in the Transaction Overview Forbion has about $133 millionRead More
To access this post, you must purchase 1 - User: Monthly Plan.